Apr. 17, 2023
- Qurgen had a Pre-IND meeting with the study team of Chinese NMPA to discuss Qurgen’s pre-IND application for a Phase I clinical trial of an anti-cancer drug, SON-DP. Qurgen communicated with NMPA officers for 2 hours and received many constructive comments and suggestions to Qurgen’s future IND application. Official IND submission will be filed at a later day.